α-tert-butyl-3-methoxybenzyl alcohol | 32578-11-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: α-tert-butyl-3-methoxybenzyl alcohol
• 英文别名: 2.2-dimethyl-1-(3-methoxyphenyl)-1-propanol；1-m-Methoxyphenyl-2,2-dimethylpropanol；1-(3-Methoxyphenyl)-2,2-dimethylpropan-1-ol
• CAS: 32578-11-3
• 化学式: C₁₂H₁₈O₂
• mdl: MFCD12153725
• 分子量: 194.274
• InChiKey: SWXBWSDLBPOHFE-UHFFFAOYSA-N

物化性质

• 沸点：
  286.3±23.0 °C(Predicted)
• 密度：
  1.001±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  α-tert-butyl-3-methoxybenzyl alcohol 在 氯化亚砜 、 乙基溴化镁 作用下， 以 乙醚 为溶剂， 反应 3.0h， 生成 meso-3,4-bis(3-methoxyphenyl)-2,2,5,5-tetramethylhexane
  参考文献：
  名称：

  烷基链分枝对雌二醇受体结合亲和力和1,2-二烷基化1,2-双（4-或3-羟苯基）乙烷雌激素和抗雌激素的内在活性的影响。

  摘要：

  在1,2-二烷基-1,2-双（4-羟苯基）乙烷雌激素的己烯雌酚（乙基，HES）和octestrol（正丙基，OCES）的α或β位置对称引入CH3取代基的影响[异丙基（1），叔丁基（2），仲丁基（3），异丁基（4）]和1,2-二烷基-1，2-二-（3-羟苯基）乙烷抗雌激素间己雌酚（乙基，MetaHES ）和间苯三酚（n-丙基，MetaOCES）[异丙基（5），叔丁基（6），仲丁基（7），异丁基（8）]对雌二醇受体（E2R）的结合亲和力和内在活性。化合物1-8的合成是通过以下方式完成的：（a）将相应的α-烷基苄醇与TiCl3 / LiAlH4还原偶联，并分离内消旋非对映异构体（化合物2-4、7和8），（b）α-叔丁基-3-甲氧基苄基氯与CoCl2 / EtMgCl并分离出内消旋结构异构体（6），以及（c）异丙基苯基酮与TiCl4 / Zn并随后氢化相应的顺式-己基- 3-烯（化合物1和5）。通过竞争性结合测定法相对于[3H]

  DOI：

  10.1021/jm00159a018
• 作为产物：
  描述：

  1-(3-甲氧基苯基)-2,2-二甲基-1-丙酮 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 生成 α-tert-butyl-3-methoxybenzyl alcohol
  参考文献：
  名称：

  替代效应。22. α-t-丁基苄基甲苯磺酸盐的溶剂分解

  摘要：

  在 80% 的丙酮水溶液 (80A) 和 80% 的乙醇水溶液 (80E) 中测定了甲苯磺酸 α-叔丁基苄基酯的溶剂分解速率，以获得一系列扩展的取代基。根据 Yukawa-Tsuno LArSR 关系，取代基效应可以线性相关，80A 中的 ρ 值分别为 -5.542 和 1.093，80E 中的 ρ 值分别为 -5.650 和 1.106。大的负 ρ 和升高的 r 值表明 kc 机制在没有亲核溶剂辅助和甲基参与的情况下在这种溶剂分解中起作用。从取代基效应的比较来看，在 α-甲基苄基氯的溶剂分解中观察到的 1.15 的升高 r 值可归因于二级苄基系统增强的共振需求特征，而不是由 SN1-SN2 引起的非线性引起的相关伪影机械变化。

  DOI：

  10.1246/bcsj.63.856

文献信息

• [EN] HUMAN ETS-RELATED GENE (ERG) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS DE GÈNES (ERG) ASSOCIÉS À L'ETS HUMAIN UTILISÉS EN TANT QU'AGENTS THÉRAPEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2018145217A1

  公开（公告）日：2018-08-16

  This invention provides compound having a structure of Formula (I): (I) Uses of such compounds for treatment of ERG, FLI1, ETV4, or ETV1 -mediated indications, including cancer. Also provided are pharmaceutical composition and methods of treating ERG, FLI1, ETV4, or ETV1-mediated indications, including cancer. The cancer may be selected from the group consisting of: prostate cancer, Ewing's sarcoma, breast cancer or pancreatic cancer.

  这项发明提供了具有以下结构的化合物：(I)：(I)。利用这些化合物治疗ERG、FLI1、ETV4或ETV1介导的疾病的用途，包括癌症。还提供了药物组合物和治疗ERG、FLI1、ETV4或ETV1介导的疾病的方法，包括癌症。癌症可以选择自前列腺癌、尤因肉瘤、乳腺癌或胰腺癌等组中的一种。
• NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS
  申请人：UNIVERSITY OF CINCINNATI

  公开号：US20160101188A1

  公开（公告）日：2016-04-14

  Compositions and methods for treating cancer in a subject are described herein. The composition includes modified nucleobases and nucleosides that are converted in the cell to nucleotides that are incorporated into growing DNA and result in termination of DNA elongation. The nucleobases and nucleotides are incorporated with a drug delivery system (DDS). The DDS includes β-cyclodextrin. The nucleobases and nucleotides are conjugated to the β-cyclodextrin by an acid labile linker that releases the nucleobases and nucleotides in the acidic environment of cancer cells. The DDS may also include a targeting ligand that targets the DDS/nucleobase or nucleotide conjugate to cancer cells. The DDS/nucleobase or nucleotide conjugate may self form into nanoparticles and may be administered to a subject with cancer in an amount effective to treat said cancer.

  本文描述了用于治疗患者癌症的组合物和方法。该组合物包括经过修饰的核碱基和核苷，这些核碱基和核苷在细胞中转化为核苷酸，并被合并到正在生长的DNA中，导致DNA延伸终止。这些核碱基和核苷与药物输送系统（DDS）一起使用。DDS包括β-环糊精。核碱基和核苷通过酸敏链连接到β-环糊精上，该链在癌细胞的酸性环境中释放核碱基和核苷。DDS还可以包括靶向配体，将DDS/核碱基或核苷共轭物靶向癌细胞。DDS/核碱基或核苷共轭物可以自行形成纳米粒子，并可以以有效治疗癌症的剂量给患者服用。
• Base-modified thymidines capable of terminating DNA synthesis are novel bioactive compounds with activity in cancer cells
  作者：Kayla M. Borland、Safnas F. AbdulSalam、Morwena J. Solivio、Matthew P. Burke、Patrick R. Wolfkiel、Sean M. Lawson、Courtney A. Stockman、Joel M. Andersen、Skyler Smith、Julia N. Tolstolutskaya、Purujit N. Gurjar、Aron P. Bercz、Edward J. Merino、Vladislav A. Litosh

  DOI：10.1016/j.bmc.2015.01.057

  日期：2015.4

  Current FDA-approved chemotherapeutic antimetabolites elicit severe side effects that warrant their improvement; therefore, we designed compounds with mechanisms of action focusing on inhibiting DNA replication rather than targeting multiple pathways. We previously discovered that 5-(alpha-substituted-2-nitrobenzyloxy)methyluridine-5 '-triphosphates were exquisite DNA synthesis terminators; therefore, we synthesized a library of 35 thymidine analogs and evaluated their activity using an MTT cell viability assay of MCF7 breast cancer cells chosen for their vulnerability to these nucleoside derivatives. Compound 3a, having an alpha-tert-butyl-2-nitro-4-(phenyl)alkynylbenzyloxy group, showed an IC50 of 9 +/- 1 mu M. The compound is more selective for cancer cells than for fibroblast cells compared with 5-fluorouracil. Treatment of MCF7 cells with 3a elicits the DNA damage response as indicated by phosphorylation of gamma-H2A. A primer extension assay of the 5 '-triphosphate of 3a revealed that 3aTP is more likely to inhibit DNA polymerase than to lead to termination events upon incorporation into the DNA replication fork. (C) 2015 Elsevier Ltd. All rights reserved.
• HARTMANN R. W., J. MED. CHEM., 29,(1986) N 9, 1668-1674
  作者：HARTMANN R. W.

  DOI：——

  日期：——
• [EN] NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS<br/>[FR] NOUVEAUX AGENTS CHIMIOTHÉRAPEUTIQUES ANTICANCÉREUX DÉLIVRÉS PAR NANO-PORTEUR
  申请人：UNIV CINCINNATI

  公开号：WO2014194250A2

  公开（公告）日：2014-12-04

  Compositions and methods for treating cancer in a subject are described herein. The composition includes modified nucleobases and nucleosides that are converted in the cell to nucleotides that are incorporated into growing DNA and result in termination of DNA elongation. The nucleobases and nucleotides are incorporated with a drug delivery system (DDS). The DDS includes β-cyclodextrin. The nucleobases and nucleotides are conjugated to the β-cyclodextrin by an acid labile linker that releases the nucleobases and nucleotides in the acidic environment of cancer cells. The DDS may also include a targeting ligand that targets the DDS/ nucleobase or nucleotide conjugate to cancer cells. The DDS/ nucleobase or nucleotide conjugate may self form into nanoparticles and may be administered to a subject with cancer in an amount effective to treat said cancer.